Phase 2 N=23 BI 2536 Second Line Monotherapy in SCLC
Carcinoma, Small Cell
Primary: Number of Participants With Objective Tumor Response — 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=74 A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.
Non-alcoholic Fatty Liver Disease (NAFLD) · Non-alcoholic Steatohepatitis (NASH)
Primary: Safety (Including Hepatic Safety) and Tolerability of MEDI0382 Compared With Placebo: Number of Participants With TEAE and SAE — 20; 22; 9; 0 Participants
Phase 2 N=70 Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With a Mild Infection of a Foot Ulcer
Diabetic Foot Ulcer
Primary: Number of Participants With a Clinical Outcome of "Clinical Cure" — 14; 7 Participants
Phase 2 N=116 A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
Brain and Central Nervous System Tumors
Primary: Phase 1b Escalation Phase: Number of Participants With Dose-Limiting Toxicities (DLTs) as Assessed by CTCAE — 0; 0; 2; 1 participants
Phase 2 N=59 A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis
Palmoplantar Pustulosis
Primary: Change From Baseline in Palmoplantar Pustulosis Psoriasis Area Severity Index (PPPASI) — -6.0; -6.1 score on a scale — p=0.944
Phase 2 N=125 PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction
Healthy · Obese
Primary: Resting Energy Expenditure After 12 Weeks of Drug Therapy (kcal/Day) — 1267; 1268 kcal/day
Phase 2 N=39 Study of Ataluren in Participants With Nonsense Mutation Aniridia
Aniridia
Primary: Percent Change From Baseline in Maximum Reading Speed of Oculus Unitas (OU) (Both Eyes) at Week 48, as Measured Using the Minnesota Low Vision Reading Test (MNREAD)…
Phase 2 N=558 A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease
Dry Eye
Primary: Part 1: Change From Baseline in Symptom Assessment in Dry Eye (SANDE) Score — -6.0; -8.1; -4.9; -1.8 Score on scale — p=0.585
Phase 2 N=44 Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype
Alpha1-Antitrypsin Deficiency
Primary: Change in Plasma Functional Alpha-1 Antitrypsin (AAT) Levels — -0.1; 2.3; 2.3; 2.1 micromole per liter — p=<0.0001
Phase 2 N=34 Measuring Ambulation, Motor, and Behavioral Outcomes With Post-Stroke Fluoxetine in Tanzania
Acute Stroke · Stroke, Ischemic
Primary: Serum Sodium Concentration — 138.7 mmol/L
Phase 2 N=30 Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals
HIV-1-infection
Primary: Concentration of Doravirine in Seminal Plasma Fluid — 127 ng/ml
Phase 2 N=54 Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Multiple Myeloma
Primary: Progression Free Survival — 16.7 Months
Phase 2 N=43 Anti-Inflammatory Agent in Sinusitis
Nasal Polyps
Primary: TOTAL POLYP SCORE (TPS) — 4.67; 5.24 units on a scale — p=<0.05
Phase 2 N=197 Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
CD19-Positive Neoplastic Cells Present · Recurrent Adult Acute Lymphoblastic Leukemia · Recurrent Chronic Lymphocytic Leukemia
Primary: Death Within 8 Weeks of the Study Cell Infusion Thought to be Definitely or Probably Related to Chimeric Antigen Receptor (CAR) T Cell Therapy — 0; 0; 1; 0 Participants
Phase 2 N=26 Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma · Metastatic Malignant Neoplasm in the Bone · Prostate Adenocarcinoma
Primary: Number of Adverse Events — 236; 14 adverse events